Squarepoint’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $26.4M | Buy |
+48,656
| New | +$27.4M | 0.03% | 573 |
|
|
2025
Q4 | – | Sell |
-31,296
| Closed | -$14.6M | – | 4929 |
|
|
2025
Q3 | $13.1M | Buy |
31,296
+22,945
| +275% | +$7.72M | 0.01% | 948 |
|
|
2025
Q2 | $2.4M | Sell |
8,351
-3,745
| -31% | -$1.12M | ﹤0.01% | 1967 |
|
|
2025
Q1 | $3.73M | Buy |
+12,096
| New | +$4.15M | ﹤0.01% | 1621 |
|
|
2024
Q2 | – | Sell |
-177,501
| Closed | -$47M | – | 4685 |
|
|
2024
Q1 | $40.8M | Buy |
177,501
+157,321
| +780% | +$35.5M | 0.07% | 324 |
|
|
2023
Q4 | $4.44M | Sell |
20,180
-20,077
| -50% | -$4.63M | 0.01% | 1471 |
|
|
2023
Q3 | $9.09M | Sell |
40,257
-4,436
| -10% | -$1.02M | 0.02% | 842 |
|
|
2023
Q2 | $9.87M | Buy |
44,693
+40,295
| +916% | +$8.93M | 0.03% | 681 |
|
|
2023
Q1 | $985K | Sell |
4,398
-1,984
| -31% | -$489K | ﹤0.01% | 1900 |
|
|
2022
Q4 | $1.77M | Buy |
+6,382
| New | +$1.61M | 0.01% | 1439 |
|
|
2022
Q3 | – | Sell |
-10,600
| Closed | -$2.37M | – | 3471 |
|
|
2022
Q2 | $2.5M | Sell |
10,600
-8,562
| -45% | -$1.74M | 0.01% | 1054 |
|
|
2022
Q1 | $3.44M | Sell |
19,162
-1,631
| -8% | -$311K | 0.01% | 872 |
|
|
2021
Q4 | $4.49M | Sell |
20,793
-17,194
| -45% | -$3.38M | 0.01% | 842 |
|
|
2021
Q3 | $7.01M | Buy |
37,987
+6,563
| +21% | +$1.29M | 0.02% | 632 |
|
|
2021
Q2 | $5.64M | Buy |
31,424
+4,103
| +15% | +$781K | 0.02% | 672 |
|
|
2021
Q1 | $4.57M | Buy |
27,321
+14,681
| +116% | +$2.45M | 0.03% | 664 |
|
|
2020
Q4 | $1.92M | Sell |
12,640
-5,302
| -30% | -$696K | 0.01% | 960 |
|
|
2020
Q3 | $1.81M | Buy |
17,942
+12,069
| +205% | +$1.32M | 0.02% | 686 |
|
|
2020
Q2 | $711K | Sell |
5,873
-44,304
| -88% | -$4.98M | 0.01% | 1123 |
|
|
2020
Q1 | $4.76M | Sell |
50,177
-71,380
| -59% | -$6.78M | 0.12% | 213 |
|
|
2019
Q4 | $10.7M | Buy |
121,557
+2,747
| +2% | +$242K | 0.06% | 276 |
|
|
2019
Q3 | $9.47M | Buy |
118,810
+93,707
| +373% | +$7.55M | 0.08% | 299 |
|
|
2019
Q2 | $1.96M | Sell |
25,103
-11,151
| -31% | -$1.04M | 0.02% | 859 |
|
|
2019
Q1 | $4.25M | Buy |
+36,254
| New | +$4.22M | 0.05% | 499 |
|
|
2018
Q4 | – | Sell |
-19,566
| Closed | -$2.5M | – | 2246 |
|
|
2018
Q3 | $2.5M | Buy |
+19,566
| New | +$2.42M | 0.03% | 631 |
|
|
2018
Q2 | – | Sell |
-3,143
| Closed | -$353K | – | 2068 |
|
|
2018
Q1 | $353K | Sell |
3,143
-25,799
| -89% | -$3.28M | 0.01% | 1239 |
|
|
2017
Q4 | $4.28M | Buy |
28,942
+18,344
| +173% | +$2.33M | 0.07% | 315 |
|
|
2017
Q3 | $1.24M | Buy |
+10,598
| New | +$1.35M | 0.02% | 659 |
|
|
2017
Q2 | – | Sell |
-3,834
| Closed | -$519K | – | 1821 |
|
|
2017
Q1 | $519K | Buy |
+3,834
| New | +$581K | 0.01% | 839 |
|
|
2016
Q4 | – | Sell |
-11,966
| Closed | -$1.41M | – | 1940 |
|
|
2016
Q3 | $1.41M | Buy |
11,966
+8,092
| +209% | +$972K | 0.09% | 258 |
|
|
2016
Q2 | $410K | Sell |
3,874
-16,302
| -81% | -$1.82M | 0.03% | 621 |
|
|
2016
Q1 | $2.25M | Buy |
20,176
+16,069
| +391% | +$2.03M | 0.17% | 147 |
|
|
2015
Q4 | $643K | Buy |
+4,107
| New | +$598K | 0.07% | 412 |
|
Other funds holding UTHR
ACA
JT
Squarepoint's UTHR Position: Q2 2026 in Review
Squarepoint opened a new position in United Therapeutics (UTHR) in Q2 2026: 48,656 shares worth $26.4M. The stake represents 0.03% of the portfolio and ranks #573 among its holdings. This is a return to the name: Squarepoint previously reported a position in UTHR as recently as Q3 2025.
Squarepoint first reported a position in UTHR in Q4 2015 and has held it in 33 quarters since. The position peaked at $40.8M in Q1 2024. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.
- Squarepoint held 48,656 shares of United Therapeutics worth $26.4M as of Q2 2026.
- United Therapeutics was a new Squarepoint position in Q2 2026.
- United Therapeutics made up 0.03% of Squarepoint's portfolio in Q2 2026, its #573 holding.
- Squarepoint first reported a position in United Therapeutics in Q4 2015 and has held it in 33 quarters since.
- Squarepoint's United Therapeutics position peaked at $40.8M in Q1 2024.
- 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.
Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.